SION 638
Alternative Names: SION-638Latest Information Update: 14 Dec 2022
Price :
$50 *
At a glance
- Originator Sionna Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cystic fibrosis